Recurrent Neuroblastoma Completed Phase 2 Trials for Alisertib (DB05220)

Also known as: Neuroblastoma Recurrent

IndicationStatusPhase
DBCOND0028756 (Recurrent Neuroblastoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01154816Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaTreatment